Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-09-30 DOI:10.1080/14760584.2025.2569037

Shahrul Mt-Isa, Justin R Chumbley, Matthew S Kelly, Jessica Weaver, Natalie Banniettis

{"title":"Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule.","authors":"Shahrul Mt-Isa, Justin R Chumbley, Matthew S Kelly, Jessica Weaver, Natalie Banniettis","doi":"10.1080/14760584.2025.2569037","DOIUrl":null,"url":null,"abstract":"Background: Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers.Research design and methods: Pooled, matching-adjusted PCV15 trials were indirectly compared to the analogous PCV20 trial for IgG response rate difference (RRD) and geometric mean concentration ratio (GMR) at the post-primary series (PPS) and post-toddler dose (PTD) timepoints.Results: At PPS, PCV15 was non-inferior for RRD and GMR as compared to PCV20 for all PCV13 serotypes. Moreover, PCV15 was superior to PCV20 for the RRDs of serotypes 1, 3, 4, 5, 6B, 9 V, and 23F and GMRs of serotypes 3, 4, 5, 6B, 9 V, and 23F at PPS. At PTD, RRDs were comparable for all PCV13 serotypes, except serotype 3, for which PCV15 was superior. PCV15 was superior for the GMRs of serotypes 3, 6B, and 23F, and comparable for the remaining serotypes at PTD. RRDs for serotypes 22F and 33F were non-inferior at both PPS and PTD.Conclusion: In a 2 + 1 schedule, PCV15 demonstrates immunogenicity comparable or superior to PCV20 across PCV13 serotypes, especially for serotype 3.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2569037","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers.

Research design and methods: Pooled, matching-adjusted PCV15 trials were indirectly compared to the analogous PCV20 trial for IgG response rate difference (RRD) and geometric mean concentration ratio (GMR) at the post-primary series (PPS) and post-toddler dose (PTD) timepoints.

Results: At PPS, PCV15 was non-inferior for RRD and GMR as compared to PCV20 for all PCV13 serotypes. Moreover, PCV15 was superior to PCV20 for the RRDs of serotypes 1, 3, 4, 5, 6B, 9 V, and 23F and GMRs of serotypes 3, 4, 5, 6B, 9 V, and 23F at PPS. At PTD, RRDs were comparable for all PCV13 serotypes, except serotype 3, for which PCV15 was superior. PCV15 was superior for the GMRs of serotypes 3, 6B, and 23F, and comparable for the remaining serotypes at PTD. RRDs for serotypes 22F and 33F were non-inferior at both PPS and PTD.

Conclusion: In a 2 + 1 schedule, PCV15 demonstrates immunogenicity comparable or superior to PCV20 across PCV13 serotypes, especially for serotype 3.

查看原文本刊更多论文

采用2 + 1接种计划的15价和20价肺炎球菌结合疫苗对儿童免疫原性的间接比较

背景：临床试验将新型肺炎球菌结合疫苗（PCVs； PCV15和PCV20）与已建立的PCV （PCV13）在常规2 + 1计划中进行了比较。本研究对健康婴幼儿的PCV15和PCV20免疫反应进行了间接比较。研究设计和方法：将合并、匹配调整后的PCV15试验与类似的PCV20试验间接比较，在初级接种后（PPS）和学步后剂量（PTD）时间点，对IgG反应率差（RRD）和几何平均浓度比（GMR）进行比较。结果：在PPS，与PCV20相比，PCV15在所有PCV13血清型的RRD和GMR方面并不逊色。此外，PCV15对血清型1、3、4、5、6B、9v和23F的rrd和血清型3、4、5、6B、9v和23F的gmr在PPS中均优于PCV20。在PTD，所有PCV13血清型的rrd具有可比性，除了血清型3，其中PCV15优于血清型3。PCV15对血清型3、6B和23F的gmr效果较好，对其余血清型的PTD效果相当。血清型22F和33F的rrd在PPS和PTD中均不差。结论：在2 + 1试验中，PCV15在PCV13血清型中表现出与PCV20相当或优于PCV20的免疫原性，特别是在3血清型中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.